Home Newsfeeds JP Morgan Maintains Overweight on Okta, Raises Price Target to $95

JP Morgan Maintains Overweight on Okta, Raises Price Target to $95

JP Morgan analyst Brian Essex maintains Okta (NASDAQ:OKTA) with a Overweight and raises the price target from $90 to $95.

byBenzinga Newsdesk

March 2, 2023

1 minute read

JP Morgan analyst Brian Essex maintains Okta (NASDAQ:OKTA) with a Overweight and raises the price target from $90 to $95.

OpenAI’s Sam Altman Proposes UAE as Testing Ground for Global AI Regulations

By Anusuya Lahiri

February 13, 9:08 AM

Microsoft backs OpenAI CEO's proposal to use UAE as 'regulatory sandbox' for AI experimentation. Altman highlights UAE's potential to lead global AI policy discussions.

MSFT

Pepe Becomes Only The Third Memecoin After Dogecoin And Shiba Inu To Reach $7B Market Cap, Adds $4B In May Alone

By Aniket Verma

May 26, 11:24 PM

In a significant milestone, frog-themed memecoin Pepe (CRYPTO: PEPE) hit $7 billion in market cap, with $4 billion added in May alone.

$DOGE

Definitive Healthcare Reports Preliminary Financial Results For Q2 FY23 Reaffirms Revenue Guidance; Restatement Of Previously Issued Financials; Sees Q2 EPS $0.08 Vs $0.05 Est.; Revenue $61M Vs $64.24M Est; FY23 Revenue $249M-$255M Vs $252.19M Est.

By Happy Mohamed

August 1, 8:54 AM

Second Quarter 2023 Financial Highlights: Revenue is expected to be $61.0 million Net loss is expected to be in the range of $11.4 million to $11.8

General
News

Moderna CEO Highlights Promising Cancer Vaccine Data: ‘Think About The Number Of Lives That Can Be Impacted’

By Erica Kollmann

December 14, 5:03 PM

Moderna, Inc. (NASDAQ: MRNA) CEO Stéphane Bancel appeared on CNBC's "Squawk Box" Thursday to discuss the company's promising new cancer vaccine developed in

MRK

JP Morgan Maintains Overweight on Okta, Raises Price Target to $95

Related Posts

OpenAI’s Sam Altman Proposes UAE as Testing Ground for Global AI Regulations

Pepe Becomes Only The Third Memecoin After Dogecoin And Shiba Inu To Reach $7B Market Cap, Adds $4B In May Alone

Definitive Healthcare Reports Preliminary Financial Results For Q2 FY23 Reaffirms Revenue Guidance; Restatement Of Previously Issued Financials; Sees Q2 EPS $0.08 Vs $0.05 Est.; Revenue $61M Vs $64.24M Est; FY23 Revenue $249M-$255M Vs $252.19M Est.

Moderna CEO Highlights Promising Cancer Vaccine Data: ‘Think About The Number Of Lives That Can Be Impacted’